Recent journals in neurology
Searching PubMed
neurology clinical advances
Searching the Web
recent neurology journal articles 2025 2026 breakthroughs
Here is a curated overview of the most recent and significant developments in neurology journals as of August 2026:
Recent Neurology Journal Highlights (2025-2026)
Top Neurology Journals to Follow
| Journal | Focus | Impact |
|---|---|---|
| Neurology (AAN) | Broad clinical neurology | Top-tier, peer-reviewed |
| Nature Reviews Neurology | Reviews & advances | High impact |
| Current Opinion in Neurology | Issue-based reviews | IF: 4.4, Ranked 45/285 |
| Frontiers in Neurology | Open-access, broad neurology | Rapid publication |
| BMJ Neurology Open | Open-access clinical | Growing rapidly |
| Journal of Cerebral Blood Flow & Metabolism | Stroke & cerebrovascular | Specialist |
| Brain Sciences | Neuroscience & neurosurgery | Open access |
Key Recent Research Themes (2025-2026)
1. Alzheimer's, Parkinson's & MS Therapeutics
A major 2025 review in the American Journal of Medicine (PMID: 41318018) summarized advances from recent clinical trials across all three major neurodegenerative diseases, covering new disease-modifying agents and biomarker-guided approaches.
2. Neurological Pain Management
A 2025 review in Cureus (PMID: 40230768) bridges innovations like neuromodulation, targeted drug delivery, and precision medicine into pain management practice.
3. Stem Cell Therapy in Neurological Disease
Published in the Journal of Cerebral Blood Flow and Metabolism, a 2025 review (PMID: 39893030) assessed the clinical translation of stem cell-based therapies for conditions including stroke, ALS, and Parkinson's.
4. Functional Neurological Disorder (FND)
A 2025 editorial in BMJ Neurology Open (PMID: 40909195) highlighted significant advances in understanding and treating FND, reflecting a rapidly evolving field.
5. Neuroimaging & Stroke Diagnosis
A 2025 article in Stroke (PMID: 40026149) proposed a new benchmarking framework for reporting neuroimaging findings in stroke research, improving reproducibility across studies.
Breaking News (August 2026)
- Orexin agonist approved for narcolepsy: The FDA approved oveporexton (Orzeyful) - the first therapy to directly restore orexin signaling for narcolepsy type 1, a major milestone in sleep neurology.
- EEG cognitive software cleared: The FDA granted 510(k) clearance to VoxNeuro's EEG/ERP-based cognitive assessment tool, enabling objective, adjunctive cognitive measurement in clinics.
- Alzheimer's GWAS meta-analysis: A consensus genome-wide association study meta-analysis for Alzheimer's disease and related dementias was highlighted as the EAN's Paper of the Month for July 2026.
- Carotid plaque & stroke recurrence: A prospective study published in Frontiers in Neurology (Aug 11, 2026) showed that AngioPLUS-derived carotid intraplaque neovascularization predicts recurrent anterior circulation stroke.
- Alpha-lipoic acid for diabetic neuropathy: A Bayesian network meta-analysis (Aug 11, 2026, Frontiers in Neurology) compared oral, IV, and sequential alpha-lipoic acid routes in diabetic peripheral neuropathy.
- Microglial neuroinflammation in hemorrhage: A new article in Neurochemical Research (Aug 8, 2026) showed that targeting microglial C5aR1 with PMX205 attenuates neuroinflammation after intracerebral hemorrhage.
Movement Disorders Focus (Current Opinion in Neurology, Aug 2026)
The current issue (Vol 39, Issue 4) covers:
- Updated dystonia classification, genetics, and therapeutics
- Paroxysmal movement disorders - new genetic insights and emerging treatments
If you'd like a deep dive into any specific neurology topic - stroke, epilepsy, dementia, movement disorders, neuroimmunology, or others - just let me know and I can pull targeted recent literature.
Tremor or dystonia recent journals on management
Searching PubMed
tremor management treatment
Searching PubMed
dystonia management treatment
Searching the Web
tremor dystonia management guidelines 2025 2026 new treatments
Here is a thorough synthesis of the most recent literature on the management of tremor and dystonia:
Tremor & Dystonia: Recent Management Literature (2024-2026)
TREMOR MANAGEMENT
1. IETF 2025 Essential Tremor Guideline (NEW)
The International Essential Tremor Foundation (IETF) published an updated guideline in December 2025 - the most current practice guideline available. Key recommendations include:
Non-pharmacological / Non-surgical:
- TAPS (Transcutaneous Afferent Patterned Stimulation) - wrist-worn devices delivering patterned electrical stimulation to peripheral nerves
- TPNS (Transcutaneous Peripheral Nerve Stimulation) - another noninvasive option
- Felix NeuroAI Wristband - FDA-cleared in 2025; an AI-driven neurostimulation wristband that continuously monitors tremor via sensors and adjusts stimulation in real time via a cloud algorithm. Worn for an average of 8.6 hours/day in trials.
Pharmacological:
- First-line: Propranolol (including long-acting), Primidone
- Second-line: Gabapentin (monotherapy or adjunctive), Topiramate, Benzodiazepines
Surgical:
- Deep Brain Stimulation (DBS) of VIM nucleus
- Focused Ultrasound (FUS) thalamotomy - significant recent evidence
- Gamma Knife Surgery (GKS)
2. Key Recent PubMed Reviews
Tremor in Parkinson's Disease (2026)
- Pavese & Ledingham, Neurodegenerative Disease Management (PMID: 40819368)
- Reviews strategies specifically for Parkinson tremor - dopaminergic therapies, DBS, and FUS, emphasizing patient-centered care optimization.
Surgical Treatment of Tremor Syndromes (2025)
- Peters et al., Movement Disorders Clinical Practice (PMID: 41424260)
- A practical clinical guide to DBS, FUS, and radiosurgery; covers patient selection across tremor types (ET, PD, cerebellar, Holmes).
Radiosurgical Thalamotomy for Tremors (2025) - Systematic Review & Meta-Analysis
- Larcipretti et al., Neurological Sciences (PMID: 38967882)
- Highest evidence tier. Evaluated efficacy and safety of Gamma Knife thalamotomy as a non-invasive ablative option.
Essential Tremor: Drug Treatments Present and Future (2025)
- Alonso-Navarro et al., Expert Review of Neurotherapeutics (PMID: 39648495)
- Covers established agents (propranolol, primidone) and emerging pipeline drugs; notes genetic pharmacology considerations (CYP2C9/CYP2C19 variants affecting primidone metabolism).
Essential Tremor - Continuum Review (2025)
- Shih, Continuum (AAN) (PMID: 40748121)
- A comprehensive case-based review of ET diagnosis and management with a focus on DBS and FUS for medically refractory patients.
Botulinum Toxin for Tremors (2025)
- Bellows & Jankovic, Toxins (PMID: 40864077)
- Reviews BoNT use in ET, PD tremor, and other tremor types. Head/voice tremor and task-specific tremors are highlighted as areas where BoNT offers meaningful benefit.
MRI-guided FUS for Tremor (2026, ASSFN Position Update)
- Hamani et al., J Neurosurg (PMID: 41894813, March 2026)
- Updated American Society for Stereotactic and Functional Neurosurgery position statement on MRgFUS for tremor management.
DYSTONIA MANAGEMENT
1. Practice Guideline: Cerebral Palsy & Dystonia (2024)
- Fehlings et al., Developmental Medicine & Child Neurology (PMID: 38640091)
- Practice Guideline update covering pharmacological and neurosurgical management - the strongest evidence-level paper in the set. Recommends:
- Oral medications: trihexyphenidyl, baclofen, levodopa (for DRD), clonazepam
- Intrathecal baclofen for generalized dystonia
- DBS of the globus pallidus internus (GPi) for primary generalized dystonia
2. Dystonia - Continuum Review (AAN, 2025)
- Pirio Richardson, Continuum (PMID: 40748115)
- A comprehensive case-based AAN review covering classification, diagnosis, and full management spectrum from BoNT to DBS.
3. Neurosurgical & Pharmacological Management (2024)
- Mohamed et al., World Journal of Psychiatry (PMID: 38808085)
- Reviews GPi-DBS outcomes across dystonia subtypes; notes that primary isolated dystonia responds best; secondary dystonias (e.g., tardive, NBIA) have variable outcomes.
4. Neurorehabilitation in Dystonia (2025)
- Kamo et al., Frontiers in Dystonia (Aug 2025)
- Addresses who benefits from rehab, what modalities to use (physiotherapy, sensory tricks training, adaptive devices, TENS, biofeedback, kinesiotape), and timing of intervention alongside BoNT or DBS.
5. Acute Dystonia & Status Dystonicus (2025)
- Lumsden, Archives of Disease in Childhood - Education & Practice (PMID: 38816180)
- Management of acute exacerbations: benzodiazepines, trihexyphenidyl, baclofen, and ICU care for status dystonicus.
6. Task-Specific Dystonia in Sports (2024) - Systematic Review
- Nijenhuis et al., Clinical Parkinsonism & Related Disorders (PMID: 38456155)
- Reviews treatment of musician's/sportsperson's dystonia: BoNT injections, sensorimotor retraining, and immobilization-retraining approaches.
7. Cervical Dystonia Pipeline (2026)
- The cervical dystonia treatment market is expanding, with botulinum toxin remaining the cornerstone. Emerging agents targeting alternative receptors and longer-duration BoNT formulations are in late-stage trials.
Summary of Management Advances at a Glance
| Domain | What's New |
|---|---|
| Essential Tremor | AI-driven wrist neurostimulators (Felix NeuroAI, FDA 2025); IETF 2025 Guideline update |
| Focused Ultrasound | ASSFN 2026 position update; improved MR thermography for targeting precision |
| Dystonia - BoNT | Longer-duration formulations in development; neurorehab adjuncts increasingly supported |
| GPi-DBS | Refined patient selection; confirmed best outcomes in primary isolated dystonia |
| Functional Dystonia | Growing recognition; psychologically-informed physiotherapy emerging as standard |
| Parkinson Tremor | Dopaminergic optimisation + DBS/FUS decision frameworks |
Would you like a deeper look at any specific area - such as focused ultrasound protocols, botulinum toxin dosing strategies, DBS programming for dystonia, or drug-refractory essential tremor options?
Any recent neurology journals
Searching PubMed
neurology stroke epilepsy dementia
Searching PubMed
multiple sclerosis Parkinson neuropathy treatment
Searching the Web
neurology journal highlights August 2026 latest articles
Here is a broad, up-to-date sweep of recent neurology publications across all major subspecialties as of August 2026:
Recent Neurology Journals - August 2026 Update
HOT OFF THE PRESS - This Week (August 2026)
Journal of Neurology (Springer) - Latest Articles
- Tardive Blepharospasm - Baizabal-Carvallo & Jankovic (Aug 10, 2026) - New characterization from leading movement disorder experts
- Gastrointestinal dysfunction in autoimmune GFAP astrocytopathy (Aug 9, 2026) - Novel manifestations of this autoimmune encephalitis
- Frontotemporal dementia - right vs. left temporal predominance (Aug 7, 2026) - Open-access clinical comparison of FTD subtypes
Frontiers in Neurology - Latest Articles (Aug 11, 2026)
- Carotid intraplaque neovascularization & recurrent stroke - Prospective cohort study using AngioPLUS ultrasound
- Non-coding RNAs in migraine pathogenesis - Molecular biomarker review
- Alpha-lipoic acid for diabetic peripheral neuropathy - Bayesian network meta-analysis comparing oral vs. IV vs. sequential routes
- Insight and executive functions in acquired brain injury - Cognitive & behavioral neurology review
Current Opinion in Neurology - August 2026 Issue (Vol 39, Issue 4)
(Ranked 45/285 in Clinical Neurology, IF: 4.4)
Key reviews in this issue:
- Tourette Syndrome - Neurophysiology, CSPTC circuit dysfunction, invasive vs. noninvasive neuromodulation
- Balance in Parkinson's Disease - Consensus roadmap using video-oculography (vHIT), VEMPs, posturography
- Dystonia - Genetic spectrum, classification, and emerging therapeutics
- Paroxysmal movement disorders - New genetic insights and therapeutic strategies
Multiple Sclerosis - High-Impact Recent Publications
| Paper | Journal | Type | Year |
|---|---|---|---|
| Tolebrutinib in Non-relapsing Secondary Progressive MS (Fox et al.) | NEJM | Phase III RCT | 2025 |
| Lipoic Acid for Progressive MS (Spain et al.) | Neurology | Phase II RCT | 2026 |
| Natalizumab for MS (Liu et al.) | Cochrane Database | Systematic Review | 2025 |
| Neuropathic pain in MS (Mohamadi et al.) | MS & Related Disorders | Network Meta-Analysis | 2025 |
| MS Disease-Modifying Algorithms 2025 (Portuguese MS Study Group) | Acta Medica Portuguesa | Practice Guideline | 2025 |
| Cognitive dysfunction in MS - pharmacological options (Fan et al.) | Frontiers in Neurology | Systematic Review | 2025 |
The NEJM tolebrutinib trial (PMID: 40202696) is particularly significant - a Phase III RCT of a BTK inhibitor (Bruton's tyrosine kinase) for non-relapsing SPMS, representing a new therapeutic class.
Stroke - Recent High-Evidence Publications
- Pre-existing dementia and adverse stroke outcomes - Systematic review & meta-analysis, Dementia & Geriatric Cognitive Disorders (PMID: 41490240, 2026)
- Risk factors for post-stroke epilepsy - Systematic review of >82,000 cases, Postgraduate Medical Journal (PMID: 40252081, 2025)
- Haemorrhagic transformation and post-stroke epilepsy - Meta-analysis, Seizure (PMID: 41124874, 2025)
- Dual antiplatelet therapy in minor stroke - Multicenter RCT, JAHA (PMID: 40194961, 2025)
- Apolipoprotein B100 & white matter as thrombolysis response mediators - J Thrombosis & Thrombolysis (Aug 8, 2026)
Parkinson's Disease - Breaking News
- Bezisterim (NE3107) - SUNRISE-PD Phase 2 Trial (Aug 7, 2026, NeurologyLive) - Showed improvements in both motor AND nonmotor PD symptoms - a potential neuroprotective anti-inflammatory agent
- Balance consensus roadmap - Current Opinion in Neurology Aug 2026 issue
- DBS programming expansion - New educational content on optimizing DBS in general neurology settings (Boston Scientific, Aug 2026)
Neurology (AAN Journal) - Recent Highlights
- Lipoic Acid Phase II RCT for Progressive MS (PMID: 41397213) - Multicenter, double-blind, measuring brain atrophy endpoints
- DEIA & equity in neurology practice - Policy article, 2025
Other Notable Recent Topics
| Topic | Key Development |
|---|---|
| Alzheimer's Disease | Neprilysin/amyloid-beta-tau axis exploration (Aug 6, 2026); GWAS consensus meta-analysis (EAN July 2026) |
| Narcolepsy | FDA approved oveporexton (Orzeyful) - first orexin-restoring therapy (Aug 5, 2026) |
| Spinal Muscular Atrophy | New multidisciplinary care literature for SMA Awareness Month (Aug 2026) |
| Epilepsy | Traditional healer-ethnopharmacology integration reviewed; post-stroke epilepsy risk factors meta-analysed |
| Brain-Heart Interactions | Meta-analysis of cardiac dysfunction in Alzheimer's, epilepsy, migraine, and TBI (PMID: 39171885) |
| EEG Advances | High-density EEG for neurological diagnosis/prognosis (Clinical Neurophysiology, 2025); FDA-cleared EEG cognitive software (VoxNeuro, Aug 2026) |
| Ataxia | Synapticure virtual ataxia care program launched (Aug 2026) |
| Lennox-Gastaut Syndrome | Longitudinal care planning and transition-of-care emphasis (Aug 2026) |
Top Journals to Bookmark
| Journal | Focus | Access |
|---|---|---|
| Neurology (AAN) | Broad clinical | Subscription |
| NEJM (Neurology section) | High-impact trials | Subscription |
| Current Opinion in Neurology | Bimonthly subspecialty reviews | Subscription |
| Journal of Neurology (Springer) | Clinical case & original research | Hybrid OA |
| Frontiers in Neurology | Open-access, rapid publication | Free |
| Movement Disorders Clinical Practice | Movement disorders | Hybrid OA |
| Continuum (AAN) | Case-based CME reviews | AAN members |
| NeurologyLive | Weekly clinical news | Free online |
| EAN Pages (eanpages.org) | European neurology monthly highlights | Free |
Would you like me to go deeper into any specific area - such as MS therapeutics, Alzheimer's biomarkers, epilepsy management, stroke interventions, or neuro-oncology?
This is a shared conversation. Sign in to Orris to start your own chat.